trending Market Intelligence /marketintelligence/en/news-insights/trending/iqtj_hwnhzqemsuj7lemfa2 content esgSubNav
In This List

Profound Medical's device to treat uterine tumors approved by Chinese regulator

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Profound Medical's device to treat uterine tumors approved by Chinese regulator

Profound Medical Corp. said the China Food and Drug Administration approved its device Sonalleve for the noninvasive treatment of uterine fibroids.

Uterine fibroids are the most common noncancerous tumors of the female reproductive tract in women, according to the company.

The Canadian device-maker said the product enables more precise and incision-free removal of diseased tissue.

Profound Medical acquired the Sonalleve MR-HIFU business from Royal Philips in 2017.